Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ADOCYNASDAQ:COGTNASDAQ:LENZNASDAQ:OCS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADOCYAdocia$11.80$11.80$9.80▼$11.80$213.43M-0.12N/AN/ACOGTCogent Biosciences$7.24-0.3%$5.58$3.72▼$12.61$826.60M1.821.31 million shs3.12 million shsLENZLENZ Therapeutics$29.78-2.3%$28.20$16.28▼$38.93$857.89M0.42188,118 shs281,102 shsOCSOculis$19.75+0.5%$18.69$10.79▼$23.08$857.97M0.3545,318 shs32,078 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADOCYAdocia0.00%0.00%0.00%0.00%0.00%COGTCogent Biosciences-0.28%-4.99%+50.21%+11.90%-18.56%LENZLENZ Therapeutics-2.30%+2.83%+5.72%+14.14%+64.26%OCSOculis+0.51%+0.10%+3.89%+0.46%+66.53%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADOCYAdociaN/AN/AN/AN/AN/AN/AN/AN/ACOGTCogent Biosciences1.747 of 5 stars3.43.00.00.01.20.00.6LENZLENZ Therapeutics1.3157 of 5 stars3.61.00.00.01.40.80.0OCSOculis2.0893 of 5 stars3.53.00.00.01.90.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADOCYAdocia 0.00N/AN/AN/ACOGTCogent Biosciences 2.75Moderate Buy$14.57101.26% UpsideLENZLENZ Therapeutics 3.17Buy$46.6056.48% UpsideOCSOculis 3.00Buy$35.3378.90% UpsideCurrent Analyst Ratings BreakdownLatest ADOCY, LENZ, OCS, and COGT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025COGTCogent BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/29/2025COGTCogent BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$21.00 ➝ $25.005/20/2025COGTCogent BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.005/9/2025OCSOculisChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$28.00 ➝ $33.005/8/2025LENZLENZ TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.005/7/2025COGTCogent BiosciencesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$8.00 ➝ $7.004/17/2025OCSOculisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$29.00 ➝ $32.004/17/2025OCSOculisChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.004/16/2025LENZLENZ TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/14/2025LENZLENZ TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight$38.00 ➝ $51.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADOCYAdocia$13.12M16.27N/AN/A($0.21) per share-56.19COGTCogent BiosciencesN/AN/AN/AN/A$1.32 per shareN/ALENZLENZ TherapeuticsN/AN/AN/AN/A$7.42 per shareN/AOCSOculis$780K1,105.49N/AN/A$1.91 per share10.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADOCYAdocia-$10.09MN/A0.00∞N/AN/AN/AN/AN/ACOGTCogent Biosciences-$255.86M-$1.84N/AN/AN/AN/A-149.79%-75.61%8/5/2025 (Estimated)LENZLENZ Therapeutics-$49.77M-$1.77N/AN/AN/AN/A-23.74%-22.65%8/13/2025 (Estimated)OCSOculis-$97.43M-$2.64N/AN/AN/A-13,788.70%-92.95%-70.03%8/19/2025 (Estimated)Latest ADOCY, LENZ, OCS, and COGT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025OCSOculis-$0.51-$0.77-$0.26-$0.77$0.22 million$0.32 million5/7/2025Q1 2025LENZLENZ Therapeutics-$0.55-$0.53+$0.02-$0.53N/AN/A5/6/2025Q1 2025COGTCogent Biosciences-$0.56-$0.52+$0.04-$0.52N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADOCYAdociaN/AN/AN/AN/AN/ACOGTCogent BiosciencesN/AN/AN/AN/AN/ALENZLENZ TherapeuticsN/AN/AN/AN/AN/AOCSOculisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADOCYAdociaN/A1.081.07COGTCogent BiosciencesN/A5.135.13LENZLENZ TherapeuticsN/A23.0923.09OCSOculisN/A4.794.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADOCYAdociaN/ACOGTCogent BiosciencesN/ALENZLENZ Therapeutics54.32%OCSOculis22.30%Insider OwnershipCompanyInsider OwnershipADOCYAdociaN/ACOGTCogent Biosciences7.29%LENZLENZ Therapeutics6.90%OCSOculisN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADOCYAdocia7818.09 millionN/ANot OptionableCOGTCogent Biosciences80113.86 million105.56 millionOptionableLENZLENZ Therapeutics11028.15 million26.20 millionN/AOCSOculis243.66 millionN/ANot OptionableADOCY, LENZ, OCS, and COGT HeadlinesRecent News About These CompaniesOculis Holding AG (NASDAQ:OCS) Sees Large Increase in Short InterestJune 17, 2025 | marketbeat.comLeerink Partnrs Forecasts Oculis' Q2 Earnings (NASDAQ:OCS)June 9, 2025 | marketbeat.comOculis Publishes Results of 2025 Annual General MeetingJune 5, 2025 | globenewswire.comOculis Publishes Results of 2025 Annual General MeetingJune 5, 2025 | globenewswire.comCitadel Advisors LLC Buys Shares of 22,911 Oculis Holding AG (NASDAQ:OCS)June 4, 2025 | marketbeat.comOculis Publishes Notifications of Transactions by Persons Discharging Managerial ResponsibilitiesJune 3, 2025 | globenewswire.comOculis to Participate in Upcoming June Investor ConferencesJune 3, 2025 | markets.businessinsider.comOculis Holding AG Announces Participation in Upcoming Investor Conferences in June 2025June 3, 2025 | quiverquant.comOculis to Participate in Upcoming June Investor ConferencesJune 3, 2025 | globenewswire.comOculis to Participate in Upcoming June Investor ConferencesJune 3, 2025 | globenewswire.comOculis Holding AG: Oculis Reports Q1 Financial Results and Provides Company UpdateMay 11, 2025 | finanznachrichten.deOculis Publishes Invitation to the Annual General MeetingMay 9, 2025 | globenewswire.comOculis Publishes Invitation to the Annual General MeetingMay 9, 2025 | globenewswire.comOculis posts widening quarterly loss as R&D spend climbsMay 9, 2025 | thepharmaletter.comOculis Holding AG (OCS) Reports Q1 Loss, Tops Revenue EstimatesMay 8, 2025 | zacks.comOculis Reports Q1 Financial Results and Provides Company UpdateMay 8, 2025 | globenewswire.comOculis Reports Q1 2025 Financial Results and Provides Company UpdateMay 8, 2025 | globenewswire.comEarnings Preview: Oculis Holding AG (OCS) Q1 Earnings Expected to DeclineMay 7, 2025 | zacks.comOculis to Present at Upcoming May Investor ConferencesMay 7, 2025 | globenewswire.comOculis to Present at Upcoming May Investor ConferencesMay 7, 2025 | globenewswire.comOculis Holding AG to Present Innovative Late-Stage Pipeline at Major Ophthalmology Conferences in May 2025May 1, 2025 | quiverquant.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADOCY, LENZ, OCS, and COGT Company DescriptionsAdocia OTCMKTS:ADOCY$11.80 0.00 (0.00%) As of 06/20/2025Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; and BioChaperone LisPram, a combination of prandial insulin with pramlintide, as well as M1Pram, a combination of insulin M1 and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and AdoGel Sema for the long-term delivery of therapeutic agents. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.Cogent Biosciences NASDAQ:COGT$7.24 -0.02 (-0.28%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$7.24 0.00 (0.00%) As of 06/24/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.LENZ Therapeutics NASDAQ:LENZ$29.78 -0.70 (-2.30%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$29.75 -0.03 (-0.10%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Oculis NASDAQ:OCS$19.69 +0.04 (+0.20%) As of 06/24/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
